文献速递慢性肾脏病水电解质与酸碱

老年和/或衰弱合并晚期肾病的糖尿病患者血糖控制的考量

Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

过去十年慢性肾脏病(CKD)与糖尿病患病率上升,使合并这两种疾病的衰弱老年患者增多,而现有指南多基于将此类患者排除在外的试验。本文综述现有指南、大型 landmark 试验及低血糖风险较低的新型降糖药,旨在平衡呈现严格血糖控制的利弊,以助临床医生与患者制定个体化管理方案。

要点

  • 现有治疗指南可能不适用于衰弱老年合并晚期 CKD 的糖尿病患者,因相关试验多将此人群排除。
  • 几乎所有现行指南推荐老年人群采用较宽松的血糖控制,理由是中远期获益未证实且短期低血糖风险高。
  • 大型 landmark 试验显示微血管和大血管并发症的潜在获益,但其对该特定人群的相关性尚不确定。

核心结论

  • 本文旨在平衡呈现严格血糖控制对老年和/或衰弱合并晚期 CKD 糖尿病患者的利弊,以帮助临床医生和患者制定个体化管理方案。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 现有指南多基于将衰弱老年合并晚期 CKD 患者排除在外的大型试验,对此类患者不一定适用。
  • 几乎所有现行指南推荐老年人群采用较宽松的血糖控制,理由是中远期获益未证实且短期低血糖风险高。
  • 大型 landmark 试验显示微血管和大血管并发症的潜在获益,但该结果对此特定人群的相关性尚不确定。
  • 试验还提示强化血糖控制危害的潜在替代解释,包括抑郁、内源性胰岛素储备低、体重指数低和药物副作用。
  • 近些年已出现低血糖风险较低的新型降糖药。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 衰弱老年合并晚期 CKD 患者多被排除在现有指南所依据的试验之外,相关管理数据匮乏。
  • 大型 landmark 试验结果对该特定人群的相关性尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The increasing prevalence of chronic kidney disease (CKD) and diabetes over the last decade has resulted in increasing numbers of frail older patients with a combination of these conditions. Current treatment guidelines may not necessarily be relevant for such patients, who are mostly excluded from the trials upon which these recommendations are based. There is a paucity of data upon which to base the management of older patients with CKD. Nearly all current guidelines recommend less-tight glycaemic control for the older population, citing the lack of proven medium-term benefits and concerns about the high short-term risk of hypoglycaemia. However, reports from large landmark trials have shown potential benefits for both microvascular and macrovascular complications, though the relevance of these findings to this specific population is uncertain. The trials have also highlighted potential alternative explanations for the hazards of intensive glycaemic control. These include depression, low endogenous insulin reserve, low body mass index and side effects of the medication. Over the last few years, newer classes of hypoglycaemic drugs with a lower risk of hypoglycaemia have emerged. This article aims to present a balanced view of advantages and disadvantages of intense glycaemic control in this group of patients, which we hope will help the clinician and patient to come to an individualized management approach.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Panduru NM, Nistor I, Groop PH, et al. Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. Nephrol Dial Transplant. 2017. PMID: 28340246. doi:10.1093/ndt/gfx021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。